SCHEMBL7120147

SCHEMBL7120147

O=c1nc[nH]c2ncn(Cc3ccc4ccccc4c3)c12

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.40
PARN O95453 1/20 0.40
CNOT7 Q9UIV1 1/20 0.40
CYP19A1 P11511 1/20 0.40
PDE10A Q9Y233 1/20 0.39
GAA P10253 1/20 0.38
NR1I2 O75469 1/20 0.38
ADORA2A P29274 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.38
ACHE P22303 1/20 0.38
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MMP13 P45452 1/20 0.37
FAAH O00519 1/20 0.37
TRPA1 O75762 1/20 0.37
KMT2A Q03164 1/20 0.37
HIF1A Q16665 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7812404 0.84 PARN (0.54) PARNCNOT7GAAALDH1A1SMN1; SMN2
SCHEMBL7977499 0.82 CYP11B1 (0.48) PARNCNOT7NR1I2ALDH1A1SMN1; SMN2
Bromide SCHEMBL6556197 0.81 SIRT2 (0.41) DAOCYP19A1PDE10AGAAADORA2A
SCHEMBL6548460 0.80 DAO (0.43) DAOCYP19A1PDE10AGAAADORA2A
SCHEMBL7985654 0.79 CNOT7 (0.42) DAOPARNCNOT7CYP19A1PDE10A
SCHEMBL6548458 0.75 TRPA1 (0.50) DAOCYP19A1PDE10AGAAADORA2A
SCHEMBL7111074 0.71 PNP (0.44) CYP19A1PDE10AADORA2AALDH1A1SMN1; SMN2
SCHEMBL7111737 0.71 PNP (0.49) DAOCYP19A1ADORA2AALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL6258586 0.70 PNP (0.48) DAOCYP19A1ADORA2AALDH1A1SMN1; SMN2
SCHEMBL7118850 0.70 BACE1 (0.49) CNOT7PDE10AADORA2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186978-A1 Novel telomerase inhibitors PHARMACIA ITALIA, SPA (IT) 2003-10-02 US claimed
WO-2001096339-A1 NOVEL TELOMERASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186978-A1 Novel telomerase inhibitors TERT, TERF2IP, TERF2 DAO 4100/4885PARN 3206/4885CNOT7 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.